Vanda Pharmaceuticals
(NASDAQ) VNDA
Vanda Pharmaceuticals Financials at a Glance
Market Cap
$395.69MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Revenue (TTM)
$217.78M
Net Income (TTM)
-$239.55M
EPS (TTM)
-$4.05
P/E Ratio
-1.63
Dividend
$0.00
Beta (Volatility)
0.73 (Low)
Dividend
$0.00
Beta (Volatility)
0.73 (Low)
Price
$6.34
Volume
12,572
Open
$6.57
Price
$6.34
Volume
12,572
Open
$6.57
Previous Close
$6.58
Daily Range
$6.29 - $6.57
52-Week Range
$4.14 - $9.94
Estimated Earnings Date
Jul 30, 2026
Dividend
$0.00
Beta (Volatility)
0.73 (Low)
Price
$6.34
Volume
12,572
Open
$6.57
Previous Close
$6.58
Daily Range
$6.29 - $6.57
52-Week Range
$4.14 - $9.94
Estimated Earnings Date
Jul 30, 2026
VNDA News
1 Pharma Stock to Avoid at All Costs
VNDA: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Vanda Pharmaceuticals
Industry
Biotechnology
Sector
Health CareEmployees
533
CEO
Mihael Hristos Polymeropoulos, MD
Website
www.vandapharma.comHeadquarters
Washington, DC 20037, US
VNDA Financials
Key Financial Metrics (TTM)
Gross Margin
92.46%
Operating Margin
-73.64%
Net Income Margin
-109.99%
Return on Equity
-61.41%
Return on Capital
-44.49%
Return on Assets
-55.26%
Earnings Yield
-61.35%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$395.69MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Shares Outstanding
60.14M
Volume
12.57K
Avg. Volume
1.03M
Financials (TTM)
Gross Profit
$201.36M
Operating Income
-$160.36M
EBITDA
-$136.24M
Operating Cash Flow
-$126.51M
Capital Expenditure
-$783.00K
Free Cash Flow
-$127.30M
Cash & ST Invst.
$202.31M
Total Debt
$13.07M
Vanda Pharmaceuticals Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$51.72M
+3.4%
Gross Profit
$46.57M
+0.1%
Gross Margin
90.05%
N/A
Market Cap
$395.69MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
N/A
Market Cap/Employee
$742.39K
N/A
Employees
533
N/A
Net Income
-$48.57M
-64.7%
EBITDA
-$44.90M
-44.3%
Quarterly Fundamentals
Total Cash
$202.31M
-40.7%
Total Debt
$13.07M
+11.3%
Accounts Receivable
$56.88M
+27.5%
Inventory
$1.70M
-11.6%
Long Term Debt
$7.05M
-4.1%
Short Term Debt
$6.02M
+37.1%
Return on Assets
-55.26%
N/A
Return on Invested Capital
-53.82%
N/A
Free Cash Flow
-$50.44M
-50.2%
Operating Cash Flow
-$50.22M
-51.5%